1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,480 | 3,780 | 08:13 | |
| 3,560 | 3,720 | 08:13 |
Chart-Typ:
Zeitraum:
| Quantum-Si Reports Third Quarter 2024 Financial Results | BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, today announced financial results for the third quarter... ► Artikel lesen |
| Quantum-Si Incorporated: Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024 | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, today announced its participation at the Human Proteome Organization (HUPO) World Congress... ► Artikel lesen |
| Quantum-Si Reports Second Quarter 2024 Financial Results | BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, today announced financial results for the second... ► Artikel lesen |
| Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
| Recursion Pharmaceuticals, Inc.: Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability | REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed... ► Artikel lesen |
| Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen |
| Tempus AI, Inc.: Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024 | Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the... ► Artikel lesen |
| Tempus AI Signs Real World Data Collaboration With BioNTech To Support Oncology Pipeline | BERLIN (dpa-AFX) - Tempus AI, Inc (TEM), a technology company using AI to advance precision medicine and patient care, Wednesday announced a multi-year real world data collaboration with BioNTech... ► Artikel lesen |
| Opening Bell: Coca-Cola, Visa, PayPal, Netflix, VF Corp, Philip Morris, Tempus AI | Die kleine Zinseuphorie der letzten Woche ist an der Wall Street zum Wochenauftakt etwas in den Hintergrund gerückt. Der Dow Jones gab 0,16 Prozent ab. Der Nasdaq 100 verlor 1,04 Prozent. Bei den Einzelthemen... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.
